Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 544 Neoplasms 384 Carcinoma, Non-Small-Cell Lung 325 Colorectal Neoplasms 296 Lung Neoplasms 237 Prostatic Neoplasms 220 Carcinoma, Hepatocellular 213 Stomach Neoplasms 155 Pancreatic Neoplasms 155 Leukemia, Myeloid, Acute 141 Uterine Cervical Neoplasms 132 Multiple Myeloma 130 Recurrence 120 Rectal Neoplasms 114 Ovarian Neoplasms 109 Neoplasm Metastasis 105 Squamous Cell Carcinoma of Head and Neck 98 Head and Neck Neoplasms 91 Triple Negative Breast Neoplasms 87 Esophageal Neoplasms 84 Glioblastoma 82 Endometrial Neoplasms 80 Small Cell Lung Carcinoma 79 Brain Neoplasms 79 Colonic Neoplasms 78 Melanoma 71 Precursor Cell Lymphoblastic Leukemia-Lymphoma 65 Hematologic Neoplasms 65 Glioma 63 Disease 60

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × Rare Tumour × Clear all

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡